Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JVS-100 in Ischemic Heart Failure
NCT01961726Phase 2Unknown
- Sponsor
- Juventas Therapeutics
- Start
- Oct 2013
- Primary completion
- Aug 2015
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JVS-100 in Ischemic Heart Failure (IHF) (3 arms), sponsored by Juventas Therapeutics. Primary endpoint: 6 Minute Walk Distance at 4 months. Status: unknown.
02
Drugs
JVS-100
03
Conditions
Ischemic Heart Failure (IHF)
Beyond the preview
Go deeper on NCT01961726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01961726.